Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies

OBJECTIVES: The phase 2 MANTA and MANTA-RAy studies aimed to determine if the oral Janus kinase 1 preferential inhibitor filgotinib affects semen parameters and sex hormones in men with inflammatory diseases. METHODS: MANTA (NCT03201445) and MANTA-RAy (NCT03926195) included men (21–65 years) with ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinisch, Walter, Hellstrom, Wayne, Dolhain, Radboud J E M, Sikka, Suresh, Westhovens, René, Mehta, Rajiv, Ritter, Timothy, Seidler, Ursula, Golovchenko, Oleksandr, Simanenkov, Vladimir, Garmish, Olena, Jeka, Sławomir, Moravcová, Radka, Rajendran, Vijay, Le Brun, Franck-Olivier, Arterburn, Sarah, Watkins, Timothy R, Besuyen, Robin, Vanderschueren, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359529/
https://www.ncbi.nlm.nih.gov/pubmed/37137672
http://dx.doi.org/10.1136/ard-2023-224017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359529/
https://www.ncbi.nlm.nih.gov/pubmed/37137672
http://dx.doi.org/10.1136/ard-2023-224017

Ejemplares similares